Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Incyte Corporation (INCY) vs Pinterest Inc (PINS) Price & Performance

Incyte CorporationTrade
Pinterest IncTrade

Price performance (Past 24H)

Key statistics

Incyte Corporation vs Pinterest Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Pinterest Inc trades at $21.4 (market cap $11.63B). The key difference: Incyte Corporation is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, Pinterest Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Pinterest Inc for 85 Days on average.

INCYPINS
Market Cap
$22.85B$11.63B
Volume
1,927,02912,792,940
Sector
HealthMedia
52-Week High
$129.93$35.24
52-Week Low
$83.80$15.42
Typical Hold Time
33 Days85 Days
Enterprise Value
$18.35B$11.55B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Incyte Corporation

Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.

Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.

Pinterest Inc

Pinterest (PINS) trades at $20.525, up 1.06% today, with a bullish technical signal from moving averages but a bearish oscillator reading. The company reported strong revenue growth to $4.22 billion in 2025, with net income of $416.86 million, and has beaten EPS estimates in recent quarters. Analyst consensus is bullish with a $27.93 price target, though insider selling and negative net cash flow trends present cautionary notes.

The outlook for PINS is positive given its revenue growth trajectory and high gross margins, but valuation multiples like a P/E of 60.38 suggest premium pricing. Risks include reliance on advertising monetization and competitive pressures. Upside potential exists if international monetization accelerates and earnings continue to exceed expectations.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

INCY
100% Buy0% Sell
Avg holding period · 33 Days
PINS
0% Buy100% Sell
Avg holding period · 85 Days

Top news

Latest headlines on both assets

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY →

About Pinterest Inc

Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.

Read more on PINS →